|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||8.65 - 8.65|
|52-week range||6.00 - 11.37|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||28.27|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s strategy to expand its footprint in Southeast Asia, an important market for the Group.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service with Accord Healthcare (‘Accord’) into France. Through this arrangement, Clinigen’s CS customers will continue to access the Accord portfolio – both UK and EU packs of product – for their clinical trials worldwide.